Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen’s Sotorasib Updates Raise New Questions For KRAS Program

Lower Dose Being Tested Against Higher Dose Under FDA Review

Executive Summary

The company provided updates on the timing of some data from its extensive clinical program for its KRAS G12C inhibitor Lumakras, but not for certain high-profile combinations.

You may also be interested in...



While Amgen Sees Success For Two Growth Drivers, Headwinds Remain

Scrip discussed key wins for sotorasib in lung cancer and tezepelumab in asthma with Amgen executives Murdo Gordon and David Reese, but COVID-19 and other challenges are looming.

Amgen’s KRAS G12C Inhibitor Shows Deep, Durable Efficacy In Lung Cancer

Results from the Phase II CodeBreak 100 study of sotorasib presented at the World Conference on Lung Cancer were included in Amgen’s applications for approvals in the US, EU and other countries. 

Seattle Genetics Win Early US FDA Approval For Tukysa, Plans Rapid Launch

Tucatinib, approved for advanced unresectable or metastatic HER2-positive breast cancer, has a list price of $18,500 per month or $111,000 for a full course. Doctors can order the drug immediately.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144266

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel